Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

References

• Mathew A, Devesa SS, Fraumeni Jr. JF, Chow WH. Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev 2002;11:171–178.
   PubMed Web of Science ®Google Scholar
• Kloth JS, Hamberg P, Mendelaar PA, Dulfer RR, van der Holt B, Eechoute K, et al. Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. Eur J Cancer 2016;56:101–106.
   PubMed Web of Science ®Google Scholar
• Ravaud A, Schmidinger M. Clinical biomarkers of response in advanced renal cell carcinoma. Ann Oncol 2013;24:293529–293542.
   Web of Science ®Google Scholar
• Zhong J, Ali AN, Voloschin AD, Liu Y, Curran Jr. WJ, Crocker IR, et al. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer 2015;121:1456–1462.
   PubMed Web of Science ®Google Scholar
• Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol 2010;28:319–327.
   PubMed Web of Science ®Google Scholar
• Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003;170:1742–1746.
   PubMed Web of Science ®Google Scholar
• Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569–1575.
   PubMed Web of Science ®Google Scholar
• Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802–811.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) genitourinary group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–970.
   PubMed Web of Science ®Google Scholar
• Margulis V, Matin SF, Wood CG. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol 2008;18:474–480.
   PubMed Web of Science ®Google Scholar
• Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015;16:293–300.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–296.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454–463.
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832–841.
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794–5799.
   PubMed Web of Science ®Google Scholar
• Escudier B, Choueiri TK, Oudard S, Szczylik C, Négrier S, Ravaud A, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007;178:1901–1905.
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors—a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470–481.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Reeves J, Hawkins R, Guo J, Nathan P, et al. Randomised, open label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC), results of the COMPARZ trial. Ann Oncol 2012;23(Suppl 9):Abstract 8LBA_PR.
   Google Scholar
• Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011;378:1931–1939.
   PubMed Web of Science ®Google Scholar
• Funakoshi T, Shimada YJ. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol 2013;52:691–702.
   PubMed Web of Science ®Google Scholar
• Nearchou A, Valachis A, Lind P, Akre O, Sandström P. Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinomatreated with tyrosine kinase inhibitors: a literature-based meta-analysis. Clin Genitourin Cancer 2015;13:280–286.
   PubMed Web of Science ®Google Scholar
• Song Y, Du C, Zhang W, Sun Y, Yang L, Cui C, et al. A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastaticrenal cell carcinoma. Asia Pac J Clin Oncol 2016;12:174–180.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009;20:1535–1542.
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49:287–297.
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763–773.
   PubMed Web of Science ®Google Scholar
• Goldstein D, Rosenberg JE, Figlin RA, Townsend RR, McCann L, Carpenter C, et al. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? Eur J Cancer 2016;53:96–104.
   PubMed Web of Science ®Google Scholar
• Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patientswith metastatic renal cell carcinoma. J Clin Oncol 2014;32:760–777.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49:1287–1296.
   PubMed Web of Science ®Google Scholar
• Wang W, Cheng J, Mallon C, Al-Marrawi MY, Holder S, Joshi M, et al. Symptomatic secondary polycythemia induced by Anti-VEGF therapy for the treatment of metastatic renal cell carcinoma: a case series and review. Clin Genitourin Cancer 2015;13:391–395.
   Google Scholar
• Alexandre I, Billemont B, Meric JB, Richard S, Rixe O. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol 2009;27:472–473.
   PubMed Web of Science ®Google Scholar
• Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008;26:4047–4048.
   PubMed Web of Science ®Google Scholar
• Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12:793–800.
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci 2007;104:17069–17074.
   PubMed Web of Science ®Google Scholar
• Van Cruijsen H, Van der Veldt AA, Hoekman K. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Biosci 2009;14:2248–2268.
   Web of Science ®Google Scholar
• Filep JG. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. Hypertension 1997;30:22–28.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, et al. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics andpotential biomarker value. Clin Cancer Res 2011;17:918–927.
   PubMed Web of Science ®Google Scholar